Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

ClinicalTrials.gov ID: NCT01984424

Public ClinicalTrials.gov record NCT01984424. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Evolocumab, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study was to evaluate the effect of 24 weeks of evolocumab administered subcutaneously (SC) every month, compared with ezetimibe, on low-density lipoprotein cholesterol (LDL-C) levels in adults with high cholesterol who are unable to tolerate an effective dose of a statin due to muscle-related side effects (MRSE).

Study identification

NCT ID: NCT01984424
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Amgen; Industry
Enrollment: 511 participants

Conditions and interventions

Conditions

Hyperlipidemia

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 10, 2013 (Actual)
Primary completion: Nov 10, 2015 (Actual)
Completion: Nov 21, 2017 (Actual)
Last update posted: Nov 29, 2018

2013 – 2017

United States locations

U.S. sites: 18
U.S. states: 14
U.S. cities: 18

Facility	City	State	ZIP	Site status
Research Site	Beverly Hills	California	90211	—
Research Site	Huntington Beach	California	92648	—
Research Site	Los Angeles	California	90048	—
Research Site	San Pedro	California	90732	—
Research Site	Atlanta	Georgia	30322	—
Research Site	Sterling	Illinois	61081	—
Research Site	Kansas City	Kansas	66160	—
Research Site	Baltimore	Maryland	21201	—
Research Site	Towson	Maryland	21204	—
Research Site	Ann Arbor	Michigan	48106	—
Research Site	Rochester	Minnesota	55905	—
Research Site	St Louis	Missouri	63110	—
Research Site	New York	New York	10029	—
Research Site	Durham	North Carolina	27710	—
Research Site	Cleveland	Ohio	44195	—
Research Site	York	Pennsylvania	17405	—
Research Site	Charleston	South Carolina	29425	—
Research Site	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01984424, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 29, 2018 · Synced Oct 22, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01984424 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →